Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

It said that 95% of people with cystic fibrosis in England will now be eligible for modulator therapy. The new drug, also ...

US biotech major Vertex Pharmaceuticals (Nasdaq: VRTX) has reached a wide-ranging reimbursement deal with NHS England for ...

Prof David Sheppard, Professor of Physiology, University of Bristol, said: ...

NHS England » NHS to roll-out new ‘triple combination’ therapy for hundreds of children and adults with cystic fibrosis ...

Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for ALYFTREK ...